Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma Ended

2024-518931-12-00 Neuroblastoma 4 2014-05-15
A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon Cancer Ended

2024-516004-42-01 MSI Negative Colorectal Cancer 4 2014-05-14
THIS IS A CLINICAL STUDY WHICH EVALUATES TREATMENT WITH CHLORAMBUCIL AND RITUXIMAB FOLLOWED BY RITUXIMAB GIVEN UNDER THE SKIN IN PATIENTS W… Ended

2023-507291-52-00 Extranodal Marginal Zone Lymphoma 4 2014-03-24
CheckMate 032:CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 032 Ended

2024-516540-25-00 Advanced or metastatic solid tumors: 1) Triple Negative 9 2013-12-11
A study, in which patients with late-stage lung cancer and changes in a gene called EGFR, will be first treated for 8 weeks with the drug er… Ended

2024-514268-18-00 Non-Small Cell Lung Cancer 4 2013-09-06
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma Ended

2023-506419-16-00 Advanced Classical Hodgkin Lymphoma 5 2013-01-08
A Phase II Study of Dasatinib in Children and Adolescents with Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolera… Ended

2024-510784-36-00 Children and Adolescents with Newly Diagnosed Chronic P 9 2009-04-27
Brightline-4: A study to test how well brigimadlin is tolerated by people with a type of cancer called dedifferentiated liposarcoma Ended

2023-504522-19-00 dedifferentiated liposarcoma 5
PembrolizuMab beyond RECIST progression and oral metroNOmic cyclophosphamide in meTAstatic UROthelial cancer: a single-arm, monocentre, phas… Ended

2024-514979-17-04 metastatic urothelial cancer 4
Phase 1 study of NG-350A plus pembrolizumab in metastatic or advanced epithelial tumours (FORTIFY) Ended

2023-503457-35-00 Epithelial tumours 9
INTERACT stomach Ended

2024-516265-37-00 Stomach Cancer with metastasis in the peritoneum 1
A Study of Valemetostat Tosylate Plus Pembrolizumab versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations Ended

2024-519671-26-00 Advanced or Metastatic Non-Small Cell Lung Cancer 9
Study of SKB264 in patients with advanced and hard-to-treat cancers who have not responded well to standard treatments. Ended

2023-508700-38-00 Metastatic or locally advanced unresectable solid tumor 4
A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LIN… Ended

2025-521489-80-00 PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER 4
ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in pati… Ended

2023-509227-41-00 Low risk of disease recurrence, defined by the followin 4
A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma Ended

2025-522054-40-00 Previously treated advanced melanoma 4
Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors Ended

2023-505070-15-00 Oncology, NSCLC and CRC 9
A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors. Ended

2023-506661-65-00 Advanced Solid Tumors 3
Trail aiming to assess the safety and clinical activity of bemarituzumab + bevacizumab in advanced/metastatic gynecological cancer overexpre… Ended

2024-516724-33-00 Advanced/metastatic gynecological cancer overexpressing 9
Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA) Ended

2023-503525-19-00 Metastatic cancer 3
A trial to show the similarity in effects, safety and immune response of FYB206 compared to Keytruda in people with metastatic non-squamous … Ended

2023-509766-37-00 NSCLC 5
INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Saf… Ended

2024-516738-36-00 Patients with malignant peritoneal mesothelioma 3
A Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy in Participants with First-line Stage IV or Recurrent NSCLC Ended

2022-503007-22-00 Non-small Cell Lung Cancer 4
STRIDER: A phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts with KRAS G12C+ NSCLC and bRain metastases Ended

2023-505721-13-00 patients with KRAS G12C+ non small cell lung cancer and 4